Coronavirus vaccine from China shows promise in animal tests


Get real time updates directly on you device, subscribe now.

Monitoring Desk:

A potential COVID-19 vaccine being developed by Chinese researchers showed promise in trials in monkeys, triggering antibodies and raising no safety issues, researchers said, and a human trial with more than 1,000 participants is under way.

The vaccine candidate, called BBIBP-CorV, induced high-level neutralising antibodies that can block the virus from infecting cells in monkeys, rats, guinea pigs and rabbits, researchers said in a paper published in online by the medical journal Cell on Saturday.

“These results support the further evaluation of BBIBP-CorV in a clinical trial,” researchers said in the paper.

BBIBP-CorV, developed by Beijing Institute of Biological Products affiliated to state-owned China National Pharmaceutical Group (Sinopharm), is among five candidates China is testing in humans.

More than 100 potential COVID-19 vaccines are in various stages of development around the world. Among front runners currently in human trials are being developed by AstraZeneca (AZN.L), Pfizer (PFE.N), BioNtech (22UAy.F), Johnson & Johnson (JNJ.N), Merck (MRK.N), Moderna (MRNA.O), Sanofi (SASY.PA) and China’s CanSino Biologics. Courtesy: Reuters

Get real time updates directly on you device, subscribe now.

You might also like